EISAI GmbH
- Pharmaceutical Sales 2009
-
Worldwide: 5.97 billion Euro
In Germany: 90 million Euro
(Financial year ended 31 March 2010)
- Product Range
- Pharmaceuticals for the treatment of disorders in the Central Nervous System (Alzheimer Dementia, Epilepsy, Generalized Anxiety Disorder), of the Digestive System (Peptic ulcer, NERD, GERD, Barrett, H.p. eradication, Inflammatory Bowel Disease) and of cronic pain as well as hypertension; pharmaceuticals for bowel preparation before examination
- Key Research Areas
-
Integrative Neuroscience, including: Alzheimer’s disease, multiple sclerosis, neuropathic pain, epilepsy, depression
Integrative Oncology including: anticancer therapies; tumour regression, tumour suppression, antibodies etc. and supportive cancer therapies; pain relief, nausea
Vascular/Immunological reaction including: acute coronary syndrome, atherothrombotic disease, sepsis, rheumatoid arthritis, psoriasis, Crohn’s disease - R&D Expenditure 2009
-
Worldwide: 1.37 billion Euro
(Financial year ended 31 March 2010)
- Employees in the Pharmaceuticals Division 2009
-
Worldwide: 11,400
Germany: 240
(Financial year ended 31 March 2010)
(All data based on corporate information, as of: 06/2010)
Unless indicated otherwise, data and keywords refer to the company's human therapeutics sector in Germany and to that of its international Group worldwide.
Unless indicated otherwise, data and keywords refer to the company's human therapeutics sector in Germany and to that of its international Group worldwide.
Suggest page
Print page
Bookmark page